leisure time -WSS

leisure time

author：Wikipedia 2025-09-28 23:44:56 - browse：5

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The Food and Drug Administration on Thursday approved an Eli Lilly drug that takes a new approach to treating ulcerative colitis, a chronic inflammatory disease that can cause intense gastrointestinal pain and distress.

The therapy, dubbed Omvoh, is an antibody that blocks IL-23p19, an immune signaling molecule that plays a key role in sustaining the disease. It’s the first treatment to target this particular pathway in ulcerative colitis. The drug’s approval comes after two late-stage trials found that patients taking Omvoh showed a significant improvement in symptoms after both three months and a year compared with those given a placebo, and that the therapy had minimal side effects.

Omvoh’s list price will be $9,593 per month for intravenous delivery and $10,360 per dose injected beneath the skin. A company spokesperson told STAT that patients who have the drug covered by commercial insurance may pay as little as $5 per month for up to 30 months.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Yancopoulos of Regeneron works to expand Dupixent success

explore

WSS

CRISPR technology availability, affordability needs to be expanded

eGenesis tests gene

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Parkinson’s finding may lead to tests and, someday, treatments

6 surprising facts about sugar

NIH director takes cautious approach to Biden drug pricing priority

focus

leisure time

focus

Medical leaders decry Supreme Court decision on affirmative action

Pfizer, Moderna say biotech, pharma drug development is a sprint

How one medical school became remarkably diverse

CRISPR technology availability, affordability needs to be expanded

Sports medicine is finally prioritizing gender equality

The surgeon had a dilemma only a Nazi medical text could resolve

Guidelines to prevent youth baseball injuries need more muscle

NIH director takes cautious approach to Biden drug pricing priority

After affirmative action ruling, medical educators look to 'holistic review'

CRISPR technology availability, affordability needs to be expanded

explore

Prior authorization will have to move faster under new Biden rule

Biotech venture capitalists face new demands from investors

Asbestos ban is immediate, but health effects will linger for decades

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Eli Lilly, Pfizer, and others want in on the online prescription market

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

hotspot

explore

Wikipedia

explore